Nuvation Bio Inc. (NUVB)

Price$4.82

Value ScoreD

Growth ScoreA

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-47.90%

Price vs S&P 500 (4W)0.64%

VGM Score64.03

Market Capitalization$1.68B

All Metrics

Book Value / Share (Quarterly)$0.92

P/TBV (Annual)10.46x

Cash Flow / Share (Quarterly)$-0.39

Price vs S&P 500 (YTD)-54.36%

Gross Margin (TTM)90.78%

Net Profit Margin (TTM)-102.06%

EPS (TTM)$-0.43

10-Day Avg Trading Volume3.93M

EPS Excl Extra (TTM)$-0.43

EPS (Annual)$-0.60

ROI (Annual)-39.81%

Gross Margin (Annual)85.22%

Cash / Share (Quarterly)$1.54

Revenue Growth QoQ (YoY)2598.70%

ROA (Last FY)-34.40%

Revenue Growth TTM (YoY)1205.52%

EBITD / Share (TTM)$-0.42

ROE (5Y Avg)-45.89%

Operating Margin (TTM)-104.99%

Cash Flow / Share (Annual)$-0.52

P/B Ratio5.27x

P/B Ratio (Quarterly)4.67x

Net Income / Employee (Annual)$-686,700

EV / Revenue (TTM)12.38x

Net Interest Coverage (TTM)-24.42x

ROA (TTM)-23.80%

EPS Incl Extra (Annual)$-0.60

Current Ratio (Annual)6.95x

Quick Ratio (Quarterly)7.04x

3-Month Avg Trading Volume4.44M

52-Week Price Return94.35%

Revenue / Employee (TTM)$480,000

Tangible BV / Share (Quarterly)$0.89

P/S Ratio (Annual)26.76x

Asset Turnover (Annual)0.11x

52-Week High$9.75

EPS Excl Extra (Annual)$-0.60

CapEx CAGR (5Y)123.44%

26-Week Price Return-39.98%

Quick Ratio (Annual)6.67x

13-Week Price Return5.47%

Total Debt / Equity (Annual)0.68x

Current Ratio (Quarterly)7.44x

Enterprise Value$1.77B

Asset Turnover (TTM)0.23x

Book Value / Share Growth (5Y)-2.24%

Revenue / Employee (Annual)$211,100

Pretax Margin (Annual)-325.31%

Cash / Share (Annual)$1.53

3-Month Return Std Dev56.15%

Net Income / Employee (TTM)$-489,900

ROE (Last FY)-66.93%

EPS Basic Excl Extra (Annual)$-0.60

Receivables Turnover (TTM)12.37x

Total Debt / Equity (Quarterly)0.67x

EPS Incl Extra (TTM)$-0.43

ROI (TTM)-27.20%

P/S Ratio (TTM)11.77x

Revenue / Share (Annual)$0.18

Tangible BV / Share (Annual)$0.85

Price vs S&P 500 (52W)69.99%

Year-to-Date Return-46.21%

5-Day Price Return-2.82%

EPS Normalized (Annual)$-0.60

ROA (5Y Avg)-35.67%

Net Profit Margin (Annual)-325.31%

Month-to-Date Return0.84%

Cash Flow / Share (TTM)$-0.38

EBITD / Share (Annual)$-0.62

Operating Margin (Annual)-338.72%

LT Debt / Equity (Annual)0.63x

ROI (5Y Avg)-40.14%

LT Debt / Equity (Quarterly)0.62x

EPS Basic Excl Extra (TTM)$-0.43

P/TBV (Quarterly)4.83x

P/B Ratio (Annual)10.08x

Inventory Turnover (TTM)1.66x

Pretax Margin (TTM)-102.06%

Book Value / Share (Annual)$0.88

Price vs S&P 500 (13W)-2.78%

Beta1.55x

Revenue / Share (TTM)$0.38

ROE (TTM)-44.10%

52-Week Low$1.57

vGradeD

gGradeA

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.01est. 0.01

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.12

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
NUVBNuvation Bio Inc.	D	A	B	$4.82
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Nuvation Bio is a biopharmaceutical company developing oncology treatments, with its lead candidate taletrectinib, an oral ROS1 inhibitor for patients with ROS1-positive non-small cell lung cancer. The clinical-stage pipeline includes additional oncology candidates at various development stages. Revenue is generated primarily through licensing agreements and research partnerships, with the majority coming from Japan.